Home  /  Resource Library  /  Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach

Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach

Article discussing a study which compared the pharmacokinetics and pharmacodynamics of rituximab and biosmilar RTXM83 in DLBCL.